Physician profile
Megan Sisk
NPI 1306132279
$20,159.88
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $819 · 2021: $936 · 2022: $4,739 · 2023: $158 · 2024: $649 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $5,221 · Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $5,221.47 |
| Food and Beverage | $1,990.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,170.80 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $5,365.34 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $589.93 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.87 | 2019-2025 | Jascayd, Ofev |
| Glaxosmithkline, LLC. | $477.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $287.63 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Merck Sharp & Dohme LLC | $255.36 | 2024-2025 | Winrevair |
| Insmed, INC. | $211.21 | 2019-2025 | Arikayce |
| Pulmonx Corporation | $151.50 | 2021-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $113.19 | 2019-2025 | |
| Grifols USA, LLC | $111.79 | 2019-2022 | |
| Mylan Specialty L.P. | $95.53 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $87.50 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Pfizer INC. | $71.03 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.42 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.04 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $65.44 | 2020-2022 | |
| Genentech USA, INC. | $61.54 | 2025 | Xolair |
| Janssen Pharmaceuticals, INC | $47.62 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $39.89 | 2019 | |
| Davol INC. | $35.28 | 2020 | |
| Inspire Medical Systems, INC. | $27.56 | 2024 | Inspire |
| Harmony Biosciences LLC | $23.35 | 2024 | |
| Veran Medical Technologies, INC. | $19.02 | 2019 | |
| Lilly USA, LLC | $16.28 | 2025 | Zepbound |
| Bioventus LLC | $16.06 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2021 | |
| Resmed Corp | $12.33 | 2019 | |
| Gilead Sciences, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Sisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.